Ons Fekih1, Sonia Triki2, Ilhem Hellara3, Fadoua Neffati2, Slaheddine Chouchane4, Mohamed Neji Gueddiche4, Mohamed Fadhel Najjar3. 1. Hôpital Universitaire Fattouma Bourguiba, laboratoire de biochimie-toxicologie, 5000 Monastir, Tunisie; Hôpital Universitaire Fattouma Bourguiba, laboratoire de recherche « biologie moléculaire appliquée aux maladies cardiovasculaires, aux néphropathies et à la pharmacogénomique » LR12SP11, 5000 Monastir, Tunisie. Electronic address: onsfekihsallem@gmail.com. 2. Hôpital Universitaire Fattouma Bourguiba, laboratoire de biochimie-toxicologie, 5000 Monastir, Tunisie; Hôpital Universitaire Fattouma Bourguiba, laboratoire de recherche « biologie moléculaire appliquée aux maladies cardiovasculaires, aux néphropathies et à la pharmacogénomique » LR12SP11, 5000 Monastir, Tunisie. 3. Hôpital Universitaire Fattouma Bourguiba, laboratoire de biochimie-toxicologie, 5000 Monastir, Tunisie. 4. Hôpital universitaire Fattouma Bourguiba, département de pédiatrie, 5000 Monastir, Tunisie.
Abstract
OBJECTIVES: We purpose to verify if paraoxonase 1 (PON1) activity may be a marker of cardiovascular risk in a young Tunisian population with type 1 diabetes (T1D). METHODS: PON1 activity was measured by a kinetic method using paraoxon as substrate. The other parameters were determined by automated methods. RESULTS: One hundred and nine children and adolescents with T1D and 97 healthy subjects were involved in this study. PON1 activity and PON1/HDL-cholesterol ratio were significantly decreased in diabetics (303 ± 174 vs. 372 ± 180 U/L and 221 ± 139 vs. 298 ± 20 1U/mmol, P=0.006, P=0.002, respectively) compared to controls. A significant increase in total cholesterol, LDL-c and microalbuminuria was observed in diabetics compared to controls. PON1 activity was decreased by 9.5% in patients with diabetes duration ≥ 6 years, by 28.4% for those with fasting glycemia ≥ 7 mmol/L (P<0.001), by 14% in those with HbA1c ≥ 8% and by 12.3% for diabetics with dyslipidemia. PON1 activity is reduced when the number of cardiovascular risk factors increases (P<0.001). CONCLUSION: PON1 seems to be associated to cardiovascular risk markers in T1D. This result remains to be seen. Nevertheless, improving PON1 activity could be a significant target for reducing cardiovascular risk.
OBJECTIVES: We purpose to verify if paraoxonase 1 (PON1) activity may be a marker of cardiovascular risk in a young Tunisian population with type 1 diabetes (T1D). METHODS:PON1 activity was measured by a kinetic method using paraoxon as substrate. The other parameters were determined by automated methods. RESULTS: One hundred and nine children and adolescents with T1D and 97 healthy subjects were involved in this study. PON1 activity and PON1/HDL-cholesterol ratio were significantly decreased in diabetics (303 ± 174 vs. 372 ± 180 U/L and 221 ± 139 vs. 298 ± 20 1U/mmol, P=0.006, P=0.002, respectively) compared to controls. A significant increase in total cholesterol, LDL-c and microalbuminuria was observed in diabetics compared to controls. PON1 activity was decreased by 9.5% in patients with diabetes duration ≥ 6 years, by 28.4% for those with fasting glycemia ≥ 7 mmol/L (P<0.001), by 14% in those with HbA1c ≥ 8% and by 12.3% for diabetics with dyslipidemia. PON1 activity is reduced when the number of cardiovascular risk factors increases (P<0.001). CONCLUSION:PON1 seems to be associated to cardiovascular risk markers in T1D. This result remains to be seen. Nevertheless, improving PON1 activity could be a significant target for reducing cardiovascular risk.